Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 10/20 | 0.46 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30350822 | 0.85 | MAP4K4 (0.49) | MAP4K4KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL19510981 | 0.85 | MAP4K4 (0.49) | MAP4K4KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL31264700 | 0.84 | POLB (0.39) | MAP4K4KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL31637211 | 0.81 | MAP4K4 (0.54) | MAP4K4TRPA1HSPB1MAPK14 | |
| SCHEMBL17609022 | 0.77 | L3MBTL1 (0.55) | MAP4K4KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL16695498 | 0.76 | MEN1 (0.51) | HSPB1MAPK14KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL9493242 | 0.75 | L3MBTL1 (0.42) | MAP4K4KDM4EALDH1A1NPSR1L3MBTL1 | |
| SCHEMBL31264722 | 0.75 | EGFR (0.39) | L3MBTL1 | |
| SCHEMBL10697201 | 0.74 | L3MBTL1 (0.41) | MAP4K4KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL958698 | 0.74 | ALDH1A1 (0.53) | MAP4K4KDM4EALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009421-A1 | COMPOUND HAVING 6-MEMBERED AROMATIC RING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2253618-A1 | COMPOUND HAVING 6-MEMBERED AROMATIC RING | Takeda Pharmaceutical Company Limited (JP) | 2010-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009421-A1 | COMPOUND HAVING 6-MEMBERED AROMATIC RING | GPR4, NR3C2, NR5A2 | MAP4K4 2519/4885TRPA1 611/4885HSPB1 2960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.